News Archive

Dishman acquired IO3S of Bern Switzerland through its wholly owned subsidiary Dishman Switzerland Ltd. IO3S is the only company in the world in the field of consultancy and research in Ozone Chemistry. It has a fully developed laboratory as well as a pilot plant for Ozone based reactions. IO3S has created a strong IP, having serviced major global pharma companies and specialty chemical companies.

(AHMEDABAD, INDIA), January 21, 2009 – Dishman Group of Ahmedabad, India, has announced capital investments of more than $33 million; $20 million in the current financial year and $13 million planned for fiscal year 2009 which begins in April. The global pharmaceutical services provider will see significant expansion of its capabilities and offerings this year, with the addition of a high-potency facility near Dishman’s headquarters in the district of Ahmedabad and a new plant in Shanghai, China.

The facility in India is a state-of-the-art, 4,300-square-meter plant catering to cytotoxic and non-cytotoxic highly active substances and one of the largest and most flexible custom-manufacturing high-potency facilities in the world. In Bavla, the plant will be managed and operated by Dishman subsidiary, Switzerland-based CARBOGEN AMCIS AG, and is scheduled to be operational mid-2009.

The facility in Shanghai will include a production plant, a warehouse, its own dedicated on-site utilities and administrative/quality control offices. Construction of the facility is fully underway and is expected to be fully staffed and operational by the second quarter of 2009.
“The new facilities in India and China will enable customers to solely collaborate with Dishman as a technical partner from early stage route development to market supply, without volume limitations. The addition of the plant in India offers customers a seamless approach to high-potency research and development, process optimization and commercial manufacturing,” said Jay Vyas, managing director of Dishman.
Dishman places a focus on safety and security, with an emphasis risk management strategy, which provides redundancy of supply in multiple Asian sites and countries and also provides ease of Asian collaboration. “Additional locations and infrastructure provide secure options that maximize speed, flexibility and cost advantages for customers with the same safety and quality standards globally,” said Vyas.

Dishman is building Asia's largest facility to manufacture Cancer drugs and other high potency drugs at its Bavla plant. This facility is designed and being commissioned by its daughter company CARBOGEN AMCIS AG (CA) who has expertise in this area. Facility will be operated by CA's Swiss team and it will produce API's for CARBOGEN AMCIS AG to offer to its customers. Company has spent 50 crore rupees in building this facility.

Dishman is venturing in to manufacturing and marketing of disinfectant and sanitization products in India, Saudi Arabia and Australia. Company will make formulated products for hospitals, domestic use and industrial disinfection. In India and Australia, this will be done by company and its Australian subsidiary where as in Saudi, this will be under a JV called Dishman Arabia Ltd. with a Saudi partner. Company expect to reach 100 crore sales in 3 years from this new division.

Dishman is building Asia’s largest facility to manufacture Cancer drugs and other high potency drugs at its Bavla plant. This facility is designed and being commissioned by its daughter company CARBOGEN AMCIS AG (CA) who has expertise in this area. Facility will be operated by CA’s Swiss team and it will product APIs for CARBOGEN AMICS AG to offer to its customers. Company has spent 50 crore rupees in building this facility.

The current production of Dishman Cholesterol and Lanoline products is sited in Veenendaal, a city in the centre of the Netherlands. Today, the supply of Vitamin D and Vitamin D analogues is still sited at the area of Solvay Pharmaceuticals. However, Dishman has recently decided to build a brand new facility for the Vitamin D Analogues in Veenendaal. The new facility will not only allow the production of the present Vitamin D Analogues, but also the development of new high potent products up to 1kg. This facility is expected to be ready in the course of 2009. From that moment the supply of Vitamin D and the Vitamin D Analogues will be concentrated in Veenendaal.

Inauguration of Unit 8 at Bavla Plant. This unit was inaugurated by Mr Jay R. Vyas and Mr Francisco Junyet (Solvay Pharmaceuticals) last 27 February 2008. This new facility has 4 floors dedicated to multi-products. See pictures of the inauguration.

DISHMAN SIGNED A CO-OPERATION & JOINT API DEVELOPMENT AGREEMENT WITH POLPHARMA - POLAND

Dishman Pharma - India and Polpharma - Poland have signed a cooperation and joint API development agreement. Polpharma is in particularly a strong player in its home market and a leader in the Central and Eastern European markets and CIS countries with a turnover of ca 400 million US dollars. Polpharma is also a CEE leader in the API sales with almost 90% of which in regulated markets including USA. Dishman group, a dedicated CRM player has ca. 200 million US dollars turnover. Both companies feel that this partnership will benefit mutually and pave the way for a stronger growth in coming years.

Theo Iliopoulos, Polpharma VP Operations and General Manager Fine Chemical said:

“As the Development and Manufacturing model changes and the Regulatory requirements become ever stricter it is crucial for Development and Manufacturing to adjust and build partnerships and networks with other groups. It will allow us to come up with solutions to meet the market expectations and sustain the increased competition between major pharmas and generic pharmas and solve different problems”. “This is the unprecedented power of doing things together" he argued, “it is the future of the pharmaceutical industry”. “Looking for such partnerships with academic centers, service providers with innovative technologies and development laboratories of proven efficiency is the way forward for an industry facing fierce competition”.

J R Vyas, Managing Director of Dishman said:

"Dishman has now strategies to cooperate with leading API players and pharma companies such as Polpharma with their strength in R&D and API plants in India as CRAM player. Such partnerships will ensure long term API manufacturing contracts to Dishman and also provide API development and DMF preparation capabilities to partners to cut short their time to market."

Dishman Pharmaceuticals and Chemicals Ltd (DPCL) announces that it has signed a Memorandum of Understanding (MoU) with Solvay Pharmaceuticals BV (Solvay), the Netherlands to acquire the fine chemicals, vitamin D and vitamin D analogues business from Solvay for an undisclosed amount. Read Press Release.

BUBENDORF, Switzerland (Jan. 27, 2010) — CARBOGEN AMCIS AG today inaugurated its new High-Potency Active Pharmaceutical Ingredient (API) facility. Located on the site of its parent company, Dishman Pharmaceuticals and Chemicals Ltd., in Ahmedabad, India, the new facility is the first of its kind to be opened in India, and one of only a few such facilities worldwide.

 

 

The inaugural event, hosted on Jan. 27, 2010, was attended by 200 people, including customers, staff and members of the local business community. The facility was opened with the help of Dr. Nigel Courtenay-Luck, a leading oncology researcher, co-founder of Antisoma, senior lecturer at Hammersmith Hospital, London, and founder of Saturn Biosciences.

 

The facility’s large-scale capacity (currently up to 1,600 L) will be capable of producing multi-tonne quantities of highly potent APIs (down to < 1 µg/m3 OEL). It is expected that most of the products will be in support of the growing demand for large volume oncology products, although there has been considerable interest in cardiovascular and central nervous system-related production.

 

“Combining CARBOGEN AMCIS’ experience in the High-Potency area with the established infrastructure and support systems on the Dishman Bavla site make this a truly unique offering for customers,” said Jay Vyas, managing director, Dishman Pharmaceuticals and Chemicals Ltd.

 

“This is a very exciting time for us,” said Charlie Johnson, High-Potency business manager for CARBOGEN AMCIS. “We are now able to offer customers first-class, engineering-controlled, Highly Potent API production across two continents. CARBOGEN AMCIS’ customers will benefit from economies of scale as their API demands grow. We also will be able to offer competitive production of API to support life-cycle management.”

 

The new facility extends the capacity of CARBOGEN AMCIS’ existing High-Potency API facilities in Bubendorf, Switzerland.

Dishman’s manufacturing site in Bavla, India, has been granted the International Safety Award by the British Safety Council due to outstanding achievements w.r.t. its SHE Management System.

Dishman offers to undertake to fully fund new dedicated cGMP /US-FDA compliant facilities for individual clients where projects have an annual value of at least 5 Mio. USD and a contract period of at least 3 years.

Dishman Europe Ltd receives the Queens Award for enterprise “International Trade”, one of Britain’s most prestigious awards for British companies

Dishman has achieved ISO 14001 and OHSAS 18001 certification of BVQI Switzerland

IPO 40 times oversubscribed. 25% of stock are issued on the Mumbai Stock Exchange.

Strong commitment of Dishman to new Vitamin D analogs & HiPo APIs

The new high containment cGMP laboratory of Dishman Netherlands was opened formally on November 27^th by Mr. Jay Vyas, Chairman and owner of the Indian Dishman Group.

Important attendees include the Serbian ambassador Mr. Cedomir Radojkovic, and different representatives from such multinationals as Pfizer and Solvay.

This project was realized with the support of several companies:  Van Spanje, Techtron, Cleangrad, de Van Looy Group, Termovent and Waldner Benelux. 

Dishman Netherlands has accomplished the construction and validation of a full cGMP production laboratory for APIs in Veenendaal, The Netherlands. The laboratory consists of 6 dedicated clean rooms with a scale of operation of up to 1 kg in addition to all standard laboratory facilities. FDA compliance audit is expected in H1 of 2010.

The decision to build this production laboratory is part of Dishman’s strategy to develop new Vitamin D analogues and high potential API’s to complement the current product portfolio.  Furthermore, to develop business opportunities with new business partners:  for contract research, product development and contract manufacturing.  

Dishman Netherlands currently offers vitamin D analogues such as alfacalcidol, calcifediol, calcitriol, & dihydrotachysterol-2. Our other products include Vitamin D3 and D2; cholesterol and lanolin alcohols. Vitamin D and vitamin D analogs are used in the food, feed and pharmaceuticals industries. Vitamin D analogues are used in the combat against Psoriases, Osteoporosis and rickets. Cholesterol is used in diverse applications such as drug delivery systems, cosmetics, animal nutrition (Shrimps) and liquid crystals.  Lanolin oils are used in cosmetics (Dusoran) and also for the treatment of leather.

The opening of this laboratory in the midst of an economic recession is a sign of the strong commitment which the Dishman Group has to its Dutch subsidiary. 

# # #

More information can be found at www.dishman-netherlands.com

# # #

Profile

Dishman Netherlands (www.dishman-netherlands.com) location in Veenendaal was founded in 1946. It was taken over by the Indian Dishman Group from the Belgian company Solvay pharmaceuticals in November 2007.

Dishman Group (www.dishmanGroup.com) is headquartered in Ahmedabad, India and is listed on the Bombay Stock Exchange (BSE). In 2008/09, Dishman had sales of over US$230m. Dishman Group is a global outsourcing partner for the pharmaceutical industry offering a portfolio of development, scale-up and manufacturing services.

The products and services offered span customers’ needs from chemical development to commercial manufacture and supply of active pharmaceutical ingredients.

 

Dishman acquires the fine chemicals, vitamin D and Vitamin D analogues business from Solvay.

back   top   print